PT98373A - Processo para a preparacao de lipoproteinas oxidadas, e tratamento de infeccoes provocadas por virus - Google Patents
Processo para a preparacao de lipoproteinas oxidadas, e tratamento de infeccoes provocadas por virus Download PDFInfo
- Publication number
- PT98373A PT98373A PT98373A PT9837391A PT98373A PT 98373 A PT98373 A PT 98373A PT 98373 A PT98373 A PT 98373A PT 9837391 A PT9837391 A PT 9837391A PT 98373 A PT98373 A PT 98373A
- Authority
- PT
- Portugal
- Prior art keywords
- blood
- lipoproteins
- oxidized
- process according
- lipoprotein
- Prior art date
Links
- 102000004895 Lipoproteins Human genes 0.000 title claims 39
- 108090001030 Lipoproteins Proteins 0.000 title claims 39
- 238000000034 method Methods 0.000 title claims 35
- 241000700605 Viruses Species 0.000 title claims 3
- 208000015181 infectious disease Diseases 0.000 title claims 3
- 239000008280 blood Substances 0.000 claims 31
- 210000004369 blood Anatomy 0.000 claims 31
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 12
- 239000001301 oxygen Substances 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 9
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 9
- 150000001840 cholesterol esters Chemical class 0.000 claims 9
- 239000007800 oxidant agent Substances 0.000 claims 8
- 150000003904 phospholipids Chemical class 0.000 claims 8
- 150000003626 triacylglycerols Chemical class 0.000 claims 8
- 239000000839 emulsion Substances 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 230000001590 oxidative effect Effects 0.000 claims 6
- 150000002978 peroxides Chemical class 0.000 claims 6
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims 6
- 102000003992 Peroxidases Human genes 0.000 claims 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 5
- 230000003647 oxidation Effects 0.000 claims 5
- 238000007254 oxidation reaction Methods 0.000 claims 5
- 108040007629 peroxidase activity proteins Proteins 0.000 claims 5
- 108090000128 Lipoxygenases Proteins 0.000 claims 4
- 102000003820 Lipoxygenases Human genes 0.000 claims 4
- 102000004316 Oxidoreductases Human genes 0.000 claims 3
- 108090000854 Oxidoreductases Proteins 0.000 claims 3
- 150000001451 organic peroxides Chemical class 0.000 claims 3
- 235000019192 riboflavin Nutrition 0.000 claims 3
- 239000002151 riboflavin Substances 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 2
- 238000005481 NMR spectroscopy Methods 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 108010071584 oxidized low density lipoprotein Proteins 0.000 claims 2
- 238000005502 peroxidation Methods 0.000 claims 2
- -1 peroxide organic Chemical class 0.000 claims 2
- 239000010948 rhodium Substances 0.000 claims 2
- 229960002477 riboflavin Drugs 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 108010093096 Immobilized Enzymes Proteins 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002211 flavins Chemical group 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000003859 lipid peroxidation Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000012460 protein solution Substances 0.000 claims 1
- 229910052703 rhodium Inorganic materials 0.000 claims 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims 1
- 125000001452 riboflavin group Chemical group 0.000 claims 1
- 150000003287 riboflavins Chemical class 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55480790A | 1990-07-18 | 1990-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT98373A true PT98373A (pt) | 1992-06-30 |
Family
ID=24214788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98373A PT98373A (pt) | 1990-07-18 | 1991-07-18 | Processo para a preparacao de lipoproteinas oxidadas, e tratamento de infeccoes provocadas por virus |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0539506A4 (fi) |
| JP (1) | JPH05508159A (fi) |
| AU (1) | AU8305691A (fi) |
| CA (1) | CA2086921A1 (fi) |
| FI (1) | FI930123A (fi) |
| IE (1) | IE912498A1 (fi) |
| PT (1) | PT98373A (fi) |
| WO (1) | WO1992001467A1 (fi) |
| ZA (1) | ZA915639B (fi) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4336641C2 (de) * | 1993-10-22 | 1995-09-07 | Deutsches Rheuma Forschungszen | Verwendung von Superoxid-Dismutase (SOD) zur Behandlung retroviraler Erkrankungen |
| EP1328289B1 (de) * | 2000-10-20 | 2008-09-03 | Hamburger Stiftung zur Förderung von Wissenschaft und Kultur | Oxidierte proteine und deren biologische und therapeutische aktivität sowie diagnostische verwendung über die hemmung der interaktion zwischen oxidierten proteinen und cd36 |
-
1991
- 1991-07-11 CA CA002086921A patent/CA2086921A1/en not_active Abandoned
- 1991-07-11 AU AU83056/91A patent/AU8305691A/en not_active Abandoned
- 1991-07-11 WO PCT/US1991/004913 patent/WO1992001467A1/en not_active Application Discontinuation
- 1991-07-11 EP EP19910914013 patent/EP0539506A4/en not_active Withdrawn
- 1991-07-11 JP JP91513333A patent/JPH05508159A/ja active Pending
- 1991-07-17 IE IE249891A patent/IE912498A1/en unknown
- 1991-07-18 ZA ZA915639A patent/ZA915639B/xx unknown
- 1991-07-18 PT PT98373A patent/PT98373A/pt not_active Application Discontinuation
-
1993
- 1993-01-12 FI FI930123A patent/FI930123A/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA915639B (en) | 1992-04-29 |
| IE912498A1 (en) | 1992-01-29 |
| JPH05508159A (ja) | 1993-11-18 |
| EP0539506A1 (en) | 1993-05-05 |
| FI930123A0 (fi) | 1993-01-12 |
| WO1992001467A1 (en) | 1992-02-06 |
| EP0539506A4 (en) | 1993-11-24 |
| AU8305691A (en) | 1992-02-18 |
| FI930123A (fi) | 1993-01-12 |
| CA2086921A1 (en) | 1992-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bocci | OZONE. | |
| Bocci et al. | Oxygen-ozone therapy in medicine: an update | |
| Bocci et al. | Oxygen/ozone as a medical gas mixture. A critical evaluation of the various methods clarifies positive and negative aspects | |
| Bocci | Ozone as Janus: this controversial gas can be either toxic or medically useful | |
| Sunnen | Ozone in medicine: overview and future directions | |
| Bocci et al. | Ozone: a new therapeutic agent in vascular diseases | |
| Bocci et al. | Mechanisms of action and chemical-biological interactions between ozone and body compartments: a critical appraisal of the different administration routes | |
| US20120039796A1 (en) | Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients | |
| Bewick et al. | Superoxide dismutase, glutathione peroxidase and catalase in the red cells of patients with malignant lymphoma | |
| Bocci et al. | Ozone in medicine | |
| Sunnen | Ozone in medicine | |
| PT98373A (pt) | Processo para a preparacao de lipoproteinas oxidadas, e tratamento de infeccoes provocadas por virus | |
| EP1181026B1 (en) | Improved method for treating mammals with modified mammalian blood | |
| Bocci | How ozone acts and how it exerts therapeutic effects | |
| Nordback et al. | The mechanism of conversion of xanthine dehydrogenase to xanthine oxidase in acute pancreatitis in the canine isolated pancreas preparation | |
| Bocci | Is ozone therapy therapeutic? | |
| Jiang et al. | Total liquid ventilation reduces lung injury in piglets after cardiopulmonary bypass | |
| Mashlool et al. | Effect of cupping treatment on some biochemical variables of thi-qar province | |
| Schumer et al. | Metabolic and microcirculatory effects of glucagon in hypovolemic shock | |
| Cakir | General aspects of ozone therapy | |
| Simonyan et al. | SUPEROXIDE-PRODUCING ASSOCIATE BETWEEN NADPH OXIDASE AND NADPH CONTAINING LIPOPROTEIN (NCL) FROM HUMAN BLOOD ERYTHROCYTES AND LEUKOCYTES MEMBRANES: ACTIVATION OF IMMUNE CELLS BY NCL. | |
| RU2110264C1 (ru) | Способ лечения токсической дифтерии | |
| Rakovsky et al. | Application of ozone in medicine | |
| Dubinina et al. | Characteristics of low molecular weight substances regulating plasma superoxide dismutase activity | |
| RU2262963C1 (ru) | Способ оптимизации терапии алкогольного абстинентного синдрома |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Laying open of patent application |
Effective date: 19920221 |
|
| FC3A | Refusal |
Effective date: 19990107 |